NCT05176509已完成1 期
A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 4
- 主要终点
- Adverse events (AEs)
研究概览
简要总结
A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must have the ability to understand and willingness to sign a written informed consent document.
- •Subjects must have histologically advanced or cytologically confirmed solid tumor.
- •Subjects have progressed on after treatment with at least one standard therapy, or intolerant of the standard therapy, or no standard therapy accessible to the patients due to any reason
- •Subject must have at least 1 unidimensional measurable disease by RECIST 1.1(Eisenhauer et al., 2009).
- •Subjects must be age 18 years or older.
- •Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Life expectancy ≥3 months based on investigator's judgement.
- •Subjects must meet the following laboratory values at the screening
- •Women of reproductive potential must have negative serum beta human chorionic gonadotropin (β -HCG) pregnancy test within 7 days of the first dose of study drugs.
- •Women of reproductive potential who are sexually active with a non-sterilized male must consistently use highly effective contraception/birth control between signing of the informed consent and 120 days after the last administration of the study drugs.
排除标准
- •Subjects have another active invasive malignancy within 5 years
- •Subjects must not have received any anticancer therapy or another investigational agent within the longer of 4 weeks or 5 half-lives before the first dose of the study treatment
- •Subjects with a history of ≥ Grade 3 immune-related adverse events resulted from previous immunotherapy.
- •History of clinically significant sensitivity or allergy to monoclonal antibodies and their excipients or known allergies to antibodies produced from Chinese hamster ovary cells, which in the opinion of the Investigator suggests an increased potential for an adverse hypersensitivity to YH003, YH001 or Pembrolizumab.
- •Primary central nervous system (CNS) malignancies or symptomatic CNS metastases.
- •History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis, or history of interstitial lung disease.
- •Subjects must not have a known or suspected history of an autoimmune disorder
- •Clinically uncontrolled intercurrent illness, including active coagulopathy, uncontrolled diabetes, psychiatric illness that would limit compliance with the study requirements and other serious medical illnesses requiring systemic therapies.
- •Has an active infection requiring systemic therapy.
- •Severe cardiovascular disease including symptomatic congestive heart failure (New York Heart Association class III or IV), unstable angina, uncontrolled hypertension, active coagulopathy, uncontrolled diabetes (blood glucose > 250 mg/dl), uncontrolled peritoneal effusion, cardiac arrhythmia, a history of myocardial infarction within 6 months or a history of arterial thromboembolic event and pulmonary embolism within 3 months of the first dose of investigational agent.
- •QTcF> 480 ms at baseline; no concomitant medications that would prolong the QT interval; no family history of long QT syndrome.
- •Subjects must not have active infection of human immunodeficiency virus (HIV), hepatitis B, hepatitis C or Covid-
- •Subjects must not have a history of primary immunodeficiency.
- •Subjects from endemic area will be specifically screened for tuberculosis. Subjects with active tuberculosis are excluded. Subjects who have received BCG vaccination may have a false positive PPD test. These subjects are eligible if they have a negative Interferon Gamma Release Assay (IGRA).
- •Subjects must not receive concurrent or prior use of an immunosuppressive agent within 4 weeks of the first dose
- •Major surgery within 4 weeks prior to study entry and Minor surgery within 2 weeks prior to the first dose.
- •Subjects must not have received any vaccine within 28 days before the first dose, and subjects, if enrolled, should not receive live vaccines during the study or for 180 days after the last dose.
研究组 & 干预措施
Intervention/treatment
Experimental
干预措施: YH003 (Drug)
Intervention/treatment
Experimental
干预措施: YH001 (Drug)
Intervention/treatment
Experimental
干预措施: Pembrolizumab (Drug)
结局指标
主要结局
Adverse events (AEs)
时间窗: up to 1 year after the last dosing
The safety will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0
Maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D)
时间窗: up to 1 year after the last dosing
The MTD and/or RP2D will be determined based on the data of safety and tolerability
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid TumorsSolid TumorNCT01363024Genentech, Inc.24
进行中（未招募）
1 期
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic MalignanciesAdvanced Hematologic MalignancyRelapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRelapsed Myelodysplastic SyndromesRefractory Myelodysplastic SyndromesRelapsed Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaNCT04891757Foghorn Therapeutics Inc.144
已完成
1 期
A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid TumorsAdvanced Solid TumorNCT05169697Eucure (Beijing) Biopharma Co., Ltd6
招募中
1 期
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.CLL/SLLWaldenstrom MacroglobulinemiaDiffuse Large B Cell LymphomaMarginal Zone LymphomaHairy Cell LeukemiaMantle Cell LymphomaFollicular LymphomaNCT04775745Newave Pharmaceutical Inc60
已完成
1 期
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid TumorsSolid TumorsNCT00942799Genzyme, a Sanofi Company87